GUARDANT HEALTH INC (GH)
US40131M1099 - Common Stock
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors
/PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of...
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
The companies are working to detect colon cancer and precancerous markers in blood and/or stool.
First Week of GH June 21st Options Trading
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
These stocks are solid buys according to the advanced AI model Claude 3, which has been touted as potentially superior to ChatGPT.
Notable Thursday Option Activity: GH, FCX, CVNA
Snag This Bargain Even Cheaper Than Chief Information Officer Kalia Did
Interesting GH Put And Call Options For May 17th
December 2025 Options Now Available For Guardant Health (GH)
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
Guardant Health stock falls after in-line outlook (NASDAQ:GH)
Guardant Health (GH) reports better-than-expected Q4 2023 financials but disappoints investors with in-line guidance and the stock hits a 52-week low. Read more here.
Guardant Health Becomes Oversold (GH)
Guardant Health Non-GAAP EPS of -$0.64 beats by $0.11, revenue of $155.1M beats by $4.31M (NASDAQ:GH)
Guardant Health (GH) reported better-than-expected Q4 results, with a non-GAAP EPS beat of $0.11 and revenue surpassing estimates by $4.31M.
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
3 Stocks to Buy for the Age of Personalized Medicine
Personalized medicine stocks can unlock significant growth from your portfolio. Here are three companies to consider.
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational...
It's JPM time! Which medtechs are expected to issue updates this week? (NASDAQ:ILMN)
Several medtech companies are expected to release financial updates this coming week when the huge annual JP Morgan Healthcare Conference convenes in SF. Read more here here.
